PrintThe Burrill Report
The Burrill Report: (November 22, 2010): StemCells Seeks Human Clinical Trial in Spinal Cord Injury (.MP3,17.29 Mb)
StemCells has filed an application with Swiss regulators to conduct a clinical study of its neural stem cell therapy to treat patients with chronic spinal cord injury in Switzerland. The move puts StemCells in a race with Geron and Neuralstem to bring stem cell-based therapies as treatments for these patients to market. We spoke to Martin McGlynn, president and CEO of StemCells, about the study, what the company has learned from a previous human clinical trial of its therapy in Battan disease, and how its approach differs from its competitors.
November 18, 2010
http://www.burrillreport.com/article-stemcells_seeks_human_clinical_trials_in_spinal_cord_injury.html
DRUG DEVELOPMENT
StemCells Seeks Human Clinical Trials in Spinal Cord Injury
Podcast: November 22, 2010[Please login to post comments]
- Life Sciences M&A; Activity Sets Annual Record with $8.3B Roche Agreement to buy Intermune, Burrill Media Reports
Press Release Read More - Fitness and Personal Health Apps Could Pose Privacy Nightmare
Senator Schumer says patients’ data could be sold to third parties without their knowledge. Read More - Intel and Fox Foundation Team to Use Smartwatches to Track Parkinson's Patients
Data from wearable devices has potential to improve monitoring and treatment. Read More - Otonomy Raises $100M in Upsized IPO
Seventy-seven life sciences companies raised $5.8 billion through IPOs by mid-August. Read More - Payers Look to Curb Spending on Specialty Drugs
Podcast: August 18, 2014 Read More - Sanofi Licenses Rights to MannKind’s Afrezza for Up to $925M
After many years of struggling, biotech lands marketing partner for inhaled insulin. Read More - New System for Classifying Cancer Could Change the Way Drugs Are Developed
Largest cancer genetic analysis reveals tumor subtype correlated to cell type rather than tissue type. Read More - Juno Therapeutics Fills Its Coffers with Another $134M
Funding for the biotech startup in hot CAR T-cell therapy space tops $300 million. Read More - Cerner Buys Siemens Health Services for $1.3B
Deal creates scale for future innovation, moving company beyond electronic medical records. Read More - Pharmas Tap Academia for Drug Discovery
Bristol-Myers teams with Allied Minds and Astellas teams with Cancer Research UK. Read More
